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EDITORIAL
We need to inhibit complement in glomerular proteinuria
In blood there are a number of inflammatory media- cells was circumstantial evidence that complement acti-
vation was pathogenic. However, animals in which anti-tors that can be instantly activated, and these must be
kept under tight constraint to prevent their inadvertent sense oligonucleotides were used to effectively eliminate
what Crry was available to limit against complementactivation. An example of such a system is that of com-
plement, which consists of more than 30 proteins. Spe- activation had significantly greater complement deposi-
tion and tubular injury. These findings show that intrinsiccialized plasma membrane proteins are present on cells
exposed to blood to limit complement activation. For complement regulation (by Crry in rats) limits tubular
complement activation in proteinuric conditions.instance, the regulators of complement activation pro-
teins, complement receptor 1 (CR1), decay accelerating A relevant question to consider, which has important
therapeutic ramifications, is whether complement acti-factor and membrane cofactor protein are widely ex-
pressed. In rodents, a genetic and functional homologue vation occurs on normal tubules in glomerular protein-
uria. The study by Hori et al suggests this is so, butto these proteins is Crry, which is an abbreviation for
CR1-related gene/protein y. does not prove it. To find proof, one has to turn to work
in the same puromycin model performed by NomuraUnder normal circumstances, the glomerulus does a
remarkable job of restricting plasma proteins from enter- et al [7]. In this study, animals that were complement
depleted with cobra venom factor, or in which comple-ing the 170 liters of daily glomerular ultrafiltrate. Hence,
the apical portions of tubular cells are exposed to a ment was inhibited with soluble recombinant CR1, had
virtual elimination of complement activation, signifi-largely protein-free solution. In the case of the comple-
ment cascade, the large sizes of nearly all of the member cantly less tubulointerstitial damage, and preserved para-
aminohippuric acid (PAH) clearance. Similar findingsproteins further restrict their passage into urine. As such,
it is not crucial to protect against complement activation were reported by this group using a model of mesangial
proliferative glomerulonephritis [8]. These studies showin the portions of tubular cells that are exposed to urine.
Appropriately, the expression of complement regulators clearly that complement activation in experimental glo-
is low in the apical regions of tubular cells in both human merular proteinuria leads to tubulointerstitial damage.
and rodent kidney [1, 2]. Furthermore, complement inhibition with CR1 reduces
In conditions in which the glomerular permselectivity this injury.
barrier is impaired, plasma proteins appear in the urinary These studies in rats are relevant to human disease.
space. Progressive glomerular diseases are invariably ac- As stated above, the limited expression of complement
companied by tubulointerstitial damage, the extent of regulators in tubular apical membranes is the case in
which is closely linked to an adverse renal outcome. both humans and rats. Complement deposits are present
It has been postulated that individual proteins such as on tubular cells in human nephrotic syndrome, which at
albumin, transferrin and lipoproteins can directly or indi- least provides circumstantial evidence that complement
rectly lead to tubulointerstitial injury [3, 4]. The various is activated [9].
proteins of the complement system are among the pro- The use of antisense oligonucleotides to eliminate ex-
teins appearing in urine in nonselective glomerular pro- pression of a particular gene product was applied by
teinuria, and their activation has also been suggested to Hori et al to show the role of Crry in tubular cells conclu-
contribute to this tubulointerstitial damage [5]. sively [6]. The applicability of this therapy to renal dis-
In this issue of Kidney International, Hori et al pro- eases has exciting possibilities given the high degree of
duced glomerular proteinuria by injecting rats with the oligonucleotide uptake by endothelial cells, and by proxi-
glomerular epithelial cell toxin, puromycin aminonucleo- mal tubular cells following glomerular filtration [10].
side [6]. Over the course of this study, animals developed However, its use in the particular setting of glomerular
morphological evidence of tubulointerstitial damage. proteinuria is unlikely to be of benefit, as identifying a
The documented deposition of C3 and C5b-9 on tubular specific target gene to abolish is problematic. Given the
likelihood that C5b-9 is pathogenic to tubules in these
circumstances, targeting one of the terminal complementKey words: end-stage renal disease, inflammation, plasma proteins,
glomerular permselectivity. proteins is a conceivable approach, but liver synthesis
would have to be eliminated. 1999 by the International Society of Nephrology
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